DOP2011000195A - Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica - Google Patents
Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinicaInfo
- Publication number
- DOP2011000195A DOP2011000195A DO2011000195A DO2011000195A DOP2011000195A DO P2011000195 A DOP2011000195 A DO P2011000195A DO 2011000195 A DO2011000195 A DO 2011000195A DO 2011000195 A DO2011000195 A DO 2011000195A DO P2011000195 A DOP2011000195 A DO P2011000195A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- actinic keratosis
- imiquimod
- treat actinic
- dose
- short
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
Se revelan y describen formulaciones farmacéuticas y métodos para el suministro tópico o transdérmico de 1-isobutil-IH-imidazo[4,5-cJ-quinolin-4-amina, también conocido como (aka) 1 -(2-metilpropil- 1H-imidazo[4,5-cjquinolin-4-amino, aka imiquimod, para tratar queratosis actínica con terapias de menor duración a Ias actualmente prescriptas para Ia crema imiquimod al 5% Aldara® comercialmente disponible, tal como actualmente se encuentra aprobada por la Administración de Alimentos y Drogas de los Estados Unidos de América (FDA). Más específicamente, también se revelan y describen formulaciones de imiquimod de menor concentración en dosis para suministrar una dosis efectiva para tratar queratosis actínica con un perfil de seguridad aceptable, pero con un régimen de dosis que es de menor duración y más conveniente para su uso por los pacientes que el régimen de dosis actualmente aprobado por la FDA para la crema imiquimod al 5% Aldara®.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13953608P | 2008-12-19 | 2008-12-19 | |
US14473109P | 2009-01-14 | 2009-01-14 | |
US20514509P | 2009-01-15 | 2009-01-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2011000195A true DOP2011000195A (es) | 2011-12-15 |
Family
ID=42316709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2011000195A DOP2011000195A (es) | 2008-12-19 | 2011-06-17 | Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica |
Country Status (27)
Country | Link |
---|---|
US (13) | US20110021555A1 (es) |
EP (1) | EP2378876B1 (es) |
AR (1) | AR074802A1 (es) |
AU (1) | AU2009335943A1 (es) |
BR (1) | BRPI0923164A2 (es) |
CL (1) | CL2009002183A1 (es) |
CO (1) | CO6400171A2 (es) |
CR (1) | CR20110338A (es) |
CY (1) | CY1121485T1 (es) |
DK (1) | DK2378876T3 (es) |
DO (1) | DOP2011000195A (es) |
EA (1) | EA201100984A1 (es) |
ES (1) | ES2720149T3 (es) |
GE (1) | GEP20146198B (es) |
HR (1) | HRP20190306T1 (es) |
HU (1) | HUE041944T2 (es) |
IL (2) | IL213628A (es) |
LT (1) | LT2378876T (es) |
MX (2) | MX346455B (es) |
PA (1) | PA8855101A1 (es) |
PE (2) | PE20100469A1 (es) |
PL (1) | PL2378876T3 (es) |
PT (1) | PT2378876T (es) |
RS (1) | RS58566B1 (es) |
SI (1) | SI2378876T1 (es) |
TW (1) | TWI442923B (es) |
WO (1) | WO2010080345A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100160368A1 (en) * | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
US20110030104A1 (en) | 2008-08-29 | 2011-02-03 | Los Alamos National Security, Llc | Nucleic acids encoding plant glutamine phenylpyruvate transaminase (GPT) and uses thereof |
US20110030089A1 (en) | 2008-08-29 | 2011-02-03 | Los Alamos National Security, Llc | Transgenic plants with enhanced growth characteristics |
GEP20146198B (en) * | 2008-12-19 | 2014-11-25 | Graceway Pharmaceuticals Llc | Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis |
WO2011008324A1 (en) | 2009-07-13 | 2011-01-20 | Graceway Pharmaceuticals, Llc | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
AU2011270724B2 (en) | 2010-06-25 | 2016-10-06 | Medicis Pharmaceutical Corporation | Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis |
US9072876B2 (en) | 2010-08-05 | 2015-07-07 | Medicis Pharmaceutical Corporation | Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream |
US9492682B2 (en) | 2011-09-14 | 2016-11-15 | Medicis Pharmaceutical Corporation | Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis |
BR112014013227A2 (pt) * | 2011-11-30 | 2017-06-13 | Merz Pharma Gmbh & Co Kgaa | uso de álcoois peguilados no tratamento de queratose actínica |
WO2013162828A1 (en) | 2012-04-27 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing |
RU2725825C2 (ru) | 2013-08-30 | 2020-07-06 | Иммьюноджен Инк. | Антитела и методы анализа для обнаружения рецептора фолиевой кислоты 1 |
US9711014B2 (en) | 2013-09-06 | 2017-07-18 | Immersion Corporation | Systems and methods for generating haptic effects associated with transitions in audio signals |
US9619980B2 (en) | 2013-09-06 | 2017-04-11 | Immersion Corporation | Systems and methods for generating haptic effects associated with audio signals |
US9576445B2 (en) | 2013-09-06 | 2017-02-21 | Immersion Corp. | Systems and methods for generating haptic effects associated with an envelope in audio signals |
JP6463744B2 (ja) * | 2013-10-08 | 2019-02-06 | イミュノジェン, インコーポレイテッド | 抗folr1免疫抱合体投薬レジメン |
EP3191103B1 (en) | 2014-09-10 | 2021-09-01 | Washington University | Compositions and methods for treatment of pre-cancerous skin lesions |
EP3349796A4 (en) | 2015-09-17 | 2019-05-29 | ImmunoGen, Inc. | THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES |
US10617693B2 (en) * | 2017-03-10 | 2020-04-14 | Athenex, Inc. | Methods of treating and/or preventing actinic keratosis |
EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA677797A (en) | 1955-11-18 | 1964-01-14 | Minnesota Mining And Manufacturing Company | Sheet material having a pressure-sensitive adhesive coating of acrylate ester copolymer |
US4722941A (en) * | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
US4411893A (en) * | 1981-08-14 | 1983-10-25 | Minnesota Mining And Manufacturing Company | Topical medicament preparations |
IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US4751087A (en) | 1985-04-19 | 1988-06-14 | Riker Laboratories, Inc. | Transdermal nitroglycerin delivery system |
US4746515A (en) | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
SE9601528D0 (sv) | 1996-04-23 | 1996-04-23 | Pharmacia Ab | Transdermally administered dextromethorphan as antitissue agent |
UA67760C2 (uk) * | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
US20030007939A1 (en) * | 1998-07-31 | 2003-01-09 | Howard Murad | Pharmaceutical compositions and methods for managing dermatological conditions |
US20020058674A1 (en) * | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
JP2002534377A (ja) | 1999-01-08 | 2002-10-15 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答調節因子を用いて粘膜関連の病態を治療するための製剤および方法 |
US20030072814A1 (en) * | 1999-12-16 | 2003-04-17 | Maibach Howard I. | Topical pharmaceutical composition for the treatment of warts |
US6894060B2 (en) * | 2000-03-30 | 2005-05-17 | 3M Innovative Properties Company | Method for the treatment of dermal lesions caused by envenomation |
US20020055517A1 (en) * | 2000-09-15 | 2002-05-09 | 3M Innovative Properties Company | Methods for delaying recurrence of herpes virus symptoms |
CA2449754A1 (en) | 2001-06-15 | 2002-12-27 | 3M Innovative Properties Company | Immune response modifiers for the treatment of periodontal disease |
IL161786A0 (en) * | 2001-11-29 | 2005-11-20 | 3M Innovative Properties Co | Pharmaceutical formulations comprising an immune |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US7893083B2 (en) * | 2003-01-06 | 2011-02-22 | Eugene Mandrea | Method of treating genital herpes |
EP1608282A4 (en) * | 2003-03-13 | 2010-12-08 | 3M Innovative Properties Co | METHODS OF DIAGNOSING SKIN LESIONS |
EP1603510B1 (en) * | 2003-03-13 | 2012-05-09 | 3M Innovative Properties Company | Methods of improving skin quality |
US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
US20040265351A1 (en) * | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
US7521459B2 (en) * | 2003-07-28 | 2009-04-21 | Metabeauty Inc. | Method for treating damaged skin |
US20090232755A1 (en) * | 2003-07-28 | 2009-09-17 | Leslie Baumann | Combination therapies for treating photodamaged skin |
CA2536578A1 (en) | 2003-09-02 | 2005-03-10 | 3M Innovative Properties Company | Methods related to the treatment of mucosal associated conditions |
CN1922137A (zh) | 2003-12-31 | 2007-02-28 | 太景生物科技股份有限公司 | 蛋白酶抑制剂 |
EP1720567A2 (en) * | 2004-02-10 | 2006-11-15 | Innate Pharma | Composition and method for the treatment of carcinoma |
US20080125485A1 (en) * | 2004-02-17 | 2008-05-29 | Action Medicines | Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis |
CA2562283A1 (en) * | 2004-04-09 | 2005-11-24 | 3M Innovative Properties Company | Methods, compositions, and preparations for delivery of immune response modifiers |
US20070196452A1 (en) | 2004-06-07 | 2007-08-23 | Jie Zhang | Flux-enabling compositions and methods for dermal delivery of drugs |
CN1286529C (zh) | 2004-06-11 | 2006-11-29 | 华中科技大学 | 具有皮肤靶向性的药物组合物及其制备方法和用途 |
US20060062755A1 (en) * | 2004-09-21 | 2006-03-23 | Woodward John R | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
DE102004049223A1 (de) * | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
US20060105028A1 (en) * | 2004-11-12 | 2006-05-18 | Jie Zhang | Systems and methods for treating warts |
US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
WO2006084251A2 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
JP2009506098A (ja) * | 2005-08-31 | 2009-02-12 | セレンティス リミテッド | 黄色ブドウ球菌(Staphylococcusaureus)のコロニー形成を特徴とする炎症性皮膚症状を治療するためのオーレオリシン阻害剤の使用 |
US8703753B2 (en) * | 2005-09-15 | 2014-04-22 | Biomas Ltd. | Use of tellurium compounds for the treatment of actinic keratosis |
US8889154B2 (en) | 2005-09-15 | 2014-11-18 | Medicis Pharmaceutical Corporation | Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation |
US20070081962A1 (en) | 2005-10-06 | 2007-04-12 | Amit Munshi | Novel delivery of immune response modifiers for removal of chronic tattoos |
GB0524962D0 (en) * | 2005-12-07 | 2006-01-18 | Pharmakodex Ltd | Topical pharmaceutical compositions |
US20070264317A1 (en) * | 2006-05-15 | 2007-11-15 | Perrigo Israel Pharmaceuticals Ltd. | Imiquimod cream formulation |
EP2046121B1 (en) * | 2006-07-14 | 2012-08-22 | Stiefel Research Australia Pty Ltd | Fatty acid pharmaceutical foam |
CA2658031C (en) | 2006-07-18 | 2015-06-02 | Graceway Pharmaceuticals, Llc | Immune response modifier foam formulations comprising imiquimod and a fatty acid |
CA2659733A1 (en) | 2006-07-31 | 2008-02-07 | 3M Innovative Properties Company | Sterilized topical compositions of 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine |
DE602007013436D1 (de) * | 2006-09-15 | 2011-05-05 | Celgene Corp | N-methylaminomethyl-isoindol-verbindungen und diese enthaltende zusammensetzungen und diese verwendende verfahren |
RS52349B (en) * | 2006-09-26 | 2012-12-31 | Celgene Corporation | 5-SUBSTITUTED HINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS |
AU2007345952C1 (en) * | 2007-01-31 | 2017-06-08 | Chongxi Yu | Positively charged water-soluble prodrugs of 1H-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates |
WO2008098232A1 (en) | 2007-02-08 | 2008-08-14 | Graceway Pharmaceuticals, Llc | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
WO2008118765A1 (en) | 2007-03-23 | 2008-10-02 | Graceway Pharmaceuticals, Llc | Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders |
US20080280943A1 (en) * | 2007-03-23 | 2008-11-13 | Slade Herbert B | Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders |
WO2008140713A1 (en) | 2007-05-08 | 2008-11-20 | The Brigham And Women's Hospital, Inc | Methods and products for treating proliferative disorders |
US8636982B2 (en) * | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
GB0715428D0 (en) | 2007-08-08 | 2007-09-19 | Imp Innovations Ltd | Compositions and uses thereof |
US20090130029A1 (en) * | 2007-11-21 | 2009-05-21 | Foamix Ltd. | Glycerol ethers vehicle and pharmaceutical compositions thereof |
WO2009069006A2 (en) * | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
KR20100117077A (ko) * | 2008-01-15 | 2010-11-02 | 다우 파마슈티컬 사이언시즈, 인코포레이티드 | 이미퀴모드 제제 |
MX2010008468A (es) | 2008-01-31 | 2010-08-30 | Curevac Gmbh | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. |
US20090246156A1 (en) * | 2008-03-31 | 2009-10-01 | Audrey Kunin | Anti-acne sunscreen composition |
AU2009251848A1 (en) * | 2008-04-03 | 2009-12-03 | Cognate 3, Llc | Compositions and methods for immunotherapy |
US9393295B2 (en) | 2008-04-28 | 2016-07-19 | Novartis Ag | Nanoparticles for use in pharmaceutical compositions |
WO2009155070A2 (en) | 2008-05-30 | 2009-12-23 | Novelix Pharmaceuticals, Inc. | Compositions and methods for treatment of inflammation and hyperkeratotic lesions |
ES2761664T3 (es) | 2008-06-26 | 2020-05-20 | Anterios Inc | Entrega dérmica |
US20100160368A1 (en) | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
KR20110090892A (ko) | 2008-10-31 | 2011-08-10 | 모베르그 데르마 아베 | 두 개 이상의 침투 증강제의 조합으로 구성되는 국소 조성물 |
GEP20146198B (en) * | 2008-12-19 | 2014-11-25 | Graceway Pharmaceuticals Llc | Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis |
WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
WO2011008324A1 (en) | 2009-07-13 | 2011-01-20 | Graceway Pharmaceuticals, Llc | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
US9072876B2 (en) * | 2010-08-05 | 2015-07-07 | Medicis Pharmaceutical Corporation | Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream |
US9492682B2 (en) * | 2011-09-14 | 2016-11-15 | Medicis Pharmaceutical Corporation | Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis |
-
2009
- 2009-12-11 GE GEAP200912310A patent/GEP20146198B/en unknown
- 2009-12-11 ES ES09837849T patent/ES2720149T3/es active Active
- 2009-12-11 WO PCT/US2009/067759 patent/WO2010080345A1/en active Application Filing
- 2009-12-11 RS RS20190210A patent/RS58566B1/sr unknown
- 2009-12-11 SI SI200931933T patent/SI2378876T1/sl unknown
- 2009-12-11 MX MX2015008994A patent/MX346455B/es unknown
- 2009-12-11 US US12/636,613 patent/US20110021555A1/en not_active Abandoned
- 2009-12-11 HU HUE09837849A patent/HUE041944T2/hu unknown
- 2009-12-11 EP EP09837849.0A patent/EP2378876B1/en active Active
- 2009-12-11 LT LTEP09837849.0T patent/LT2378876T/lt unknown
- 2009-12-11 EA EA201100984A patent/EA201100984A1/ru unknown
- 2009-12-11 BR BRPI0923164A patent/BRPI0923164A2/pt not_active Application Discontinuation
- 2009-12-11 MX MX2011001555A patent/MX2011001555A/es active IP Right Grant
- 2009-12-11 AU AU2009335943A patent/AU2009335943A1/en not_active Abandoned
- 2009-12-11 PL PL09837849T patent/PL2378876T3/pl unknown
- 2009-12-11 PT PT09837849T patent/PT2378876T/pt unknown
- 2009-12-11 DK DK09837849.0T patent/DK2378876T3/en active
- 2009-12-17 TW TW098143460A patent/TWI442923B/zh active
- 2009-12-17 CL CL2009002183A patent/CL2009002183A1/es unknown
- 2009-12-18 PE PE2009001323A patent/PE20100469A1/es not_active Application Discontinuation
- 2009-12-18 AR ARP090104978A patent/AR074802A1/es unknown
- 2009-12-18 PA PA20098855101A patent/PA8855101A1/es unknown
- 2009-12-18 PE PE2014000347A patent/PE20142367A1/es not_active Application Discontinuation
-
2011
- 2011-06-16 IL IL213628A patent/IL213628A/en active IP Right Grant
- 2011-06-17 CR CR20110338A patent/CR20110338A/es unknown
- 2011-06-17 DO DO2011000195A patent/DOP2011000195A/es unknown
- 2011-07-08 US US13/179,402 patent/US20110263634A1/en not_active Abandoned
- 2011-07-08 US US13/179,336 patent/US20110263633A1/en not_active Abandoned
- 2011-07-08 US US13/179,315 patent/US8222270B2/en active Active
- 2011-07-08 US US13/179,363 patent/US20110257217A1/en not_active Abandoned
- 2011-07-12 US US13/181,507 patent/US20110257219A1/en not_active Abandoned
- 2011-07-12 US US13/181,499 patent/US8236816B2/en active Active
- 2011-07-13 CO CO11087690A patent/CO6400171A2/es not_active Application Discontinuation
- 2011-07-13 US US13/182,433 patent/US8299109B2/en active Active
- 2011-07-17 US US13/184,556 patent/US20110263636A1/en not_active Abandoned
- 2011-07-18 US US13/184,579 patent/US20110263637A1/en not_active Abandoned
-
2012
- 2012-08-06 US US13/568,003 patent/US9370509B2/en active Active
-
2016
- 2016-06-20 US US15/187,751 patent/US10238644B2/en active Active
-
2017
- 2017-10-22 IL IL255163A patent/IL255163B/en active IP Right Grant
-
2019
- 2019-02-05 US US16/268,230 patent/US11318130B2/en active Active
- 2019-02-14 CY CY20191100200T patent/CY1121485T1/el unknown
- 2019-02-14 HR HRP20190306TT patent/HRP20190306T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2011000195A (es) | Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica | |
BR112014031394A8 (pt) | Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral | |
PE20180203A1 (es) | Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificacion para su uso como principio activo farmaceutico | |
NZ605888A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain | |
UA115131C2 (uk) | Сполуки боронатного ефіру і його фармацевтичні рецептури | |
BR112015010106A2 (pt) | Dosagem e administração de terapias para câncer com oligonucleotídeo | |
EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
MX2012005689A (es) | Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos. | |
NZ595467A (en) | Sublingual pharmaceutical composition comprising a neutral oil | |
CO6710926A2 (es) | Compuestos de n-heteroarilo | |
WO2012145575A3 (en) | Therapy for leukemia | |
AR074240A1 (es) | Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
BR112012008345A2 (pt) | regime de dosagem para a administração de um anticorpo biespecífico de epcamxcd3 | |
AR088267A1 (es) | Derivados, de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden a los mismos y sus usos | |
MX336923B (es) | Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales. | |
MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
CO6592015A2 (es) | Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal | |
GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
AR075866A1 (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica. | |
WO2013022312A3 (ko) | C y p 4 a 저해제를 유효성분으로 함유하는 당뇨병 또는 지방간의 예방 또는 치료용 약학적 조성물 | |
UY32375A (es) | Formulaciones de imiquimod de baja concentración de dosis y regimenes de dosis de corta duración para tratar queratosis actínica | |
BR112013004714A2 (pt) | "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos" |